The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα

Biochemical Pharmacology

Volumn 84, Issue 1, 2012, Pages 52-58

  Yalowich, Jack C ^a,b   Wu, Xing ^c   Zhang, Rui ^c   Kanagasabai, Ragu ^a   Hornbaker, Marisa ^b   Hasinoff, Brian B ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cell cycle analysis; Dp44mT; Iron; Thiosemicarbazone; Topoisomerase II ; Triapine

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE II ALPHA; ETOPOSIDE; MESSENGER RNA; PBR322 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL LINE; CELL STRAIN K 562; CHO CELL; COVALENT BOND; CROSS RESISTANCE; DNA PROTEIN COMPLEX; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNODETECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN TARGETING; TREATMENT FAILURE;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL PROLIFERATION; CHO CELLS; CRICETINAE; DNA CLEAVAGE; DNA TOPOISOMERASES, TYPE II; DNA, CATENATED; DNA-BINDING PROTEINS; FLOW CYTOMETRY; HUMANS; K562 CELLS; PYRIDINES; THIOSEMICARBAZONES;

EID: 84860685279     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.03.021     Document Type: Article

References (36)

1. E.C. Moore, and A.C. Sartorelli The inhibition of ribonucleotide reductase by α-(N)-heterocyclic carboxaldehyde thiosemicarbazones A. Sartorelli, Inhibitors of ribonucleoside diphosphate reductase activity International encyclopedia of pharmacology and therapeutics vol. 128 1989 Pergamon New York 203 215
2. R.A. Finch, M. Liu, S.P. Grill, W.C. Rose, R. Loomis, and K.M. Vasquez Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity Biochem Pharmacol 59 2000 983 991
3. D.R. Richardson, P.C. Sharpe, D.B. Lovejoy, D. Senaratne, D.S. Kalinowski, and M. Islam Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity J Med Chem 49 2006 6510 6521
4. Z. Kovacevic, D.S. Kalinowski, D.B. Lovejoy, Y. Yu, Y.S. Rahmanto, and P.C. Sharpe The medicinal chemistry of novel iron chelators for the treatment of cancer Curr Top Med Chem 11 2011 483 499
5. C.M. Nutting, C.M. van Herpen, A.B. Miah, S.A. Bhide, J.P. Machiels, and J. Buter Phase II study of 3-AP triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma Ann Oncol 20 2009 1275 1279
6. J. Yuan, D.B. Lovejoy, and D.R. Richardson Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment Blood 104 2004 1450 1458
7. M. Whitnall, J. Howard, P. Ponka, and D.R. Richardson A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics Proc Natl Acad Sci USA 103 2006 14901 14906
8. D.B. Lovejoy, P.J. Jansson, U.T. Brunk, J. Wong, P. Ponka, and D.R. Richardson Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes Cancer Res 71 2011 5871 5880
9. B.B. Hasinoff, and D. Patel The iron chelator Dp44mT does not protect myocytes against doxorubicin J Inorg Biochem 103 2009 1093 1101
10. V.A. Rao, J. Zhang, S.R. Klein, P. Espandiari, A. Knapton, and J.S. Dickey The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats Cancer Chemother Pharmacol 68 2011 1125 1134
11. Y. Yu, Y.S. Rahmanto, C.L. Hawkins, and D.R. Richardson The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity Mol Pharmacol 79 2011 921 931
12. Y. Yu, and D.R. Richardson Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1 J Biol Chem 286 2011 15413 15427
13. V.A. Rao, S.R. Klein, K.K. Agama, E. Toyoda, N. Adachi, and Y. Pommier The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIα in breast cancer cells Cancer Res 69 2009 948 957
14. J.L. Nitiss Targeting DNA topoisomerase II in cancer chemotherapy Nat Rev Cancer 9 2009 338 350
15. J.E. Deweese, and N. Osheroff The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing Nucleic Acids Res 37 2009 738 748
16. Y. Pommier, E. Leo, H. Zhang, and C. Marchand DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem Biol 17 2010 421 433
17. C. Niu, J. Li, T.W. Doyle, and S-H. Chen Synthesis of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) Tetrahedron 54 1998 6311 6318
18. B.B. Hasinoff, X. Wu, J.C. Yalowich, V. Goodfellow, R.S. Laufer, and O. Adedayo Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects Anticancer Drugs 17 2006 825 837
19. C. Fattman, W.P. Allan, B.B. Hasinoff, and J.C. Yalowich Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells Biochem Pharmacol 52 1996 635 642
20. M.K. Ritke, and J.C. Yalowich Altered gene expression in human leukemia K562 cells selected for resistance to etoposide Biochem Pharmacol 46 1993 2007 2020
21. R. Zhang, X. Wu, J.C. Yalowich, and B.B. Hasinoff Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents Bioorg Med Chem 19 2011 7023 7032
22. B.B. Hasinoff, X. Wu, O.V. Krokhin, W. Ens, K.G. Standing, and J.L. Nitiss Biochemical and proteomics approaches to characterize topoisomerase IIα cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIα Mol Pharmacol 67 2005 937 947
23. H. Liang, X. Wu, L.J. Guziec, F.S. Guziec Jr., K.K. Larson, and J. Lang A structure-based 3D-QSAR study of anthrapyrazole analogs of the anticancer agents losoxantrone and piroxantrone J Chem Inf Model 46 2006 1827 1835
24. D.A. Burden, S.J. Froelich-Ammon, and N. Osheroff Topoisomerase II-mediated cleavage of plasmid DNA Methods Mol Biol 95 2001 283 289
25. D. Subramanian, C.S. Furbee, and Muller M.T.I.C.E Bioassay Isolating in vivo complexes of enzyme to DNA Methods Mol Biol 95 2001 137 147
26. Pfister TD, Khin S, Agama K, Hollingshead M, Sooryakumar D, Pommier Y, et al. A novel validated quantitiative pharmacodynamic topoisomerase I covalent-complex immunoassay. AACR-NCI-EORTC International Conference 2009. Abstract Number: C224.
27. M.K. Ritke, W.P. Allan, C. Fattman, N.N. Gunduz, and J.C. Yalowich Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells Mol Pharmacol 46 1994 58 66
28. L.H. Jensen, A. Renodon-Corniere, I. Wessel, S.W. Langer, B. Sokilde, and E.V. Carstensen Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition Mol Pharmacol 61 2002 1235 1243
29. M.K. Ritke, D. Roberts, W.P. Allan, J. Raymond, V.V. Bergoltz, and J.C. Yalowich Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells Br J Cancer 69 1994 687 697
30. L.A. Zwelling, M. Hinds, D. Chan, J. Mayes, K.L. Sie, and E. Parker Characterization of an amsacrine-resistant line of human leukemia cells: evidence for a drug-resistant form of topoisomerase II J Biol Chem 264 1989 16411 16420
31. J.L. Nitiss DNA topoisomerase II and its growing repertoire of biological functions Nat Rev Cancer 9 2009 327 337
32. B.B. Hasinoff, and E.H. Herman Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc Toxicol 7 2007 140 144
33. R. Zhang, X. Wu, L.J. Guziec, F. Guziec Jr., G-L. Chee, and J.C. Yalowich Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents Bioorg Med Chem 18 2010 3974 3984
34. D.T. Ross, U. Scherf, M.B. Eisen, C.M. Perou, C. Rees, and P. Spellman Systematic variation in gene expression patterns in human cancer cell lines Nat Genet 24 2000 227 235
35. R. Velez-Cruz, J.N. Riggins, J.S. Daniels, H. Cai, F.P. Guengerich, and L.J. Marnett Exocyclic DNA lesions stimulate DNA cleavage mediated by human topoisomerase IIα in vitro and in cultured cells Biochemistry 44 2005 3972 3981
36. M. Sabourin, and N. Osheroff Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions Nucleic Acids Res 28 2000 1947 1954